AIM ImmunoTech (AIM) Stock Price, News & Analysis

Company Overview

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Key Stats

• Today's Range: $2.40 to $2.57
• 50-Day Range: $2.36 to $9.50
• 52-Week Range: $2.33 to $37.80
• Volume: 57,587 shs
• Average Volume: 65,962 shs
• Market Capitalization: $6.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $275.00
• Consensus Rating: Buy

AIM ImmunoTech Stock Analysis - MarketRank™

AIM ImmunoTech scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AIM ImmunoTech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AIM ImmunoTech are expected to decrease in the coming year, from ($0.30) to ($0.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AIM ImmunoTech is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AIM ImmunoTech is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AIM ImmunoTech has a P/B Ratio of 12.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AIM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AIM ImmunoTech does not currently pay a dividend.

Dividend Growth

AIM ImmunoTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AIM.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for AIM ImmunoTech this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

3 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.02% of the stock of AIM ImmunoTech is held by insiders.

Percentage Held by Institutions

Only 12.02% of the stock of AIM ImmunoTech is held by institutions.

AIM Stock Analysis - Frequently Asked Questions

How have AIM shares performed this year?

AIM ImmunoTech's stock was trading at $19.80 on January 1st, 2025. Since then, AIM shares have decreased by 87.6% and is now trading at $2.4470.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) announced its quarterly earnings results on Wednesday, November, 15th. The company reported ($16.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($11.00) by $5.00. The company had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative net margin of 12,594.21% and a negative trailing twelve-month return on equity of 421.73%.

When did AIM ImmunoTech's stock split?

AIM ImmunoTech's stock reverse split before market open on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are AIM ImmunoTech's major shareholders?

Top institutional shareholders of AIM ImmunoTech include Corient Private Wealth LLC (1.31%). Insiders that own company stock include Thomas K Equels, Peter W Rodino III, Stewart Appelrouth and Nancy Bryan.
View institutional ownership trends.

How do I buy shares of AIM ImmunoTech?

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), iBio (IBIO), Vaxart (VXRT), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO) and T2 Biosystems (TTOO).

Company Calendar

• Last Earnings: 11/15/2023
• Today: 8/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:AIM
• CIK: 946644
• Web: aimimmuno.com
• Phone: (352) 448-7797
• Fax: 215-988-1739
• Employees: 20
• Year Founded: 1990

Price Target and Rating

• Average Price Target for AIM ImmunoTech: $275.00
• High Price Target: $450.00
• Low Price Target: $100.00
• Potential Upside/Downside: +11,138.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($24.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.96 million
• Net Margins: -12,594.21%
• Pretax Margin: -12,594.21%
• Return on Equity: -421.73%
• Return on Assets: -147.54%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 0.75
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: $121 thousand
• Price / Sales: 54.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 12.24

Miscellaneous

• Outstanding Shares: 2,709,000
• Free Float: 68,740,000
• Market Cap: $6.63 million
• Optionable: Not Optionable
• Beta: 0.88